Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-10
2005-05-10
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S454000, C514S455000
Reexamination Certificate
active
06890951
ABSTRACT:
The present invention relates to the use of a composition that increases central nervous system GABA levels in a mammal, for the treatment of addiction to drugs of abuse and modification of behavior associated with addiction to drugs of abuse in said mammal.
REFERENCES:
patent: 3639607 (1972-02-01), Phillips
patent: 4540582 (1985-09-01), Seiler et al.
patent: 4595697 (1986-06-01), Seiler et al.
patent: 4621145 (1986-11-01), Frieben et al.
patent: 5189064 (1993-02-01), Blum et al.
patent: 5869498 (1999-02-01), Mayer et al.
patent: 5942241 (1999-08-01), Chasin et al.
patent: 5948787 (1999-09-01), Merrill et al.
patent: 5958459 (1999-09-01), Chasin et al.
patent: 5968551 (1999-10-01), Oshlack et al.
patent: 6007841 (1999-12-01), Caruso
patent: 6054451 (2000-04-01), Caruso
patent: 6077538 (2000-06-01), Merrill et al.
patent: 6103261 (2000-08-01), Chasin et al.
patent: 6107330 (2000-08-01), Nabeshima et al.
patent: 6143322 (2000-11-01), Sackler et al.
patent: 6541520 (2003-04-01), Dewey et al.
patent: WO 8903211 (1989-04-01), None
patent: WO 9800130 (1998-01-01), None
patent: WO 9921540 (1999-05-01), None
patent: WO 0007583 (2000-02-01), None
patent: WO 0023059 (2000-04-01), None
patent: WO 0044374 (2000-08-01), None
patent: WO 0050020 (2000-08-01), None
patent: WO 0061140 (2000-10-01), None
patent: WO 0066108 (2000-11-01), None
Morgan et al., “Longterm Cocaine Administration May Alter Specific Gabaergic Pathways”,Abstracts Society for Neuroscience,23:1942 (1997).
Kushner et al., “Comparison of the Effects of Vigabatrin on Cocaine Self-Administration and Food Reinforcement”,Abstracts Society for Neuroscience,23:1942 (1997).
Dewey et al., “GABAergic Attenuation of Cocaine-Induced Dopamine Release and Locomotor Activity”,Synapse,25:393-398 (1997).
Morgan et al., “Effects of Pharmacologic Increases in Brain GABA Levels on Cocaine-Induced Changes in Extracellular Dopamine”,Synapse28:60-65 (1998).
Kushner et al., “Gamma-vinyl GABA Attenuates Cocaine-Induced Lowering of Brain Stimulation Reward Thresholds”,Psychopharmacology133:383-388 (1997).
Porter et al., “Antiepileptic Drugs”,Basic and Clinical Pharmacology, ed. by Katzung, B.G., Appelton and Lange, Stamford, CTpp. 386-408 (1998).
Takada et al., “Drug Dependence Study on Vigabatrin in Rhesis Monkeys and Rats”,Arzneim.-Forsch Drug Res47(II), 1087-1092 (1997).
Nisell et al., “Nicotine Dependence, Midbrain Dopamine Systems and Psychiatric Disorders”,Pharmacology&Toxicology76:157-162 (1995).
Nisell et al., “Infusion of Nicotine in the Ventral Tegmental Area or the Nucleus Accumbens of the Rat Differentially Affects Accumbal Dopamine Release”,Pharmacology&Toxicology,75:348-352 (1994).
Fudala et al., “Pharmacologic Characterization of Nicotine-Induced Conditioned Place Preference”,Pharmacol Biochem Behav22(2) 237-241 (1985).
Clarke et al., “Apparent Absence of Nicotene-Induced Conditioned Place Preference in Rats”Psychopharmacology,92: 84-88 (1987).
Clarke et al., “Evidence That Mesolimbic Dopaminergic Activation Underlies the Locomotor Stimulant Action of Nicotine in Rats”,The Journal of Pharmacology and Experimental Therapeutics,246:701-708 (1988).
Henningfield et al., “Control of Behavior by Intravenous Nicotine Injections in Human Subjects”,Pharmacology Biochemistry&Behavior,19:1021-1026 (1983).
Jarvik et al., “Pharmacological Treatment of Tobacco Dependence”,Pharmacology Biochemistry&Behavior,30:279-294 (1988).
Henningfield et al., “Cigarette Smokers Self-Administer Intravenous Nicotine”,Pharmacology Biochemistry&Behavior19:887-890 (1983).
Nisell et al., “Systemic Nicotine-Induced Dopamine Release in the Rat Nucleus Accumbens is Regulated by Nicotinic Receptors in the Ventral Tegmental Area”,Synapse16:36-44 (1994).
Pontieri et al., “Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs”Nature382:255-257 (1996).
Di Chiara et al., “Drugs Abused by Humans Preferentially Increase Synaptic Dopamine Concentrations in the Mesolimbic System of Freely Moving Rats”,Proc. Natl. Acad. Sci. USA,85:5274-5278 (1988).
Damsma et al., “Lack of Tolerance to Nicotine-Induced Dopamine Release in the Nucleus Accumbens”,European Journal of Pharmacology,168:363-368 (1989).
Imperato et al., “Nicotine Preferentially Stimulates Dopamine Release in the Limbic System of Freely Moving Rats”European Journal of Pharmacology,132:337-338 (1986).
Brazell et al., “Acute Administration of Nicotine Increases the In Vivo Extracellular Levels of Dopamine, 3,4-Dihydroxyphenylacetic Acid and Ascorbic Acid Preferentially in the Nucleus Accumbens of the Rat: Comparison with Caudate-Putamen”,Neuropharmacology29:1177-1185 (1990).
Horan et al., “Nicotine Produces Conditioned Place Preference in Lewis But Not Fischer 344 Rats”,Synapse26:93-94 (1997).
Lepore et al., “Conditioned Place Preference Induced by Δ9-Tetrahydrocannabinol: Comparison with Cocaine, Morphine, and Food Reward”,Life Sciences,56:2073-2080 (1995).
Sora et al., “Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice”Proc. Natl. Acad. Sci. USA95:7699-7704 (1998).
Valentine et al., “Self-Administration in Rats Allowed Unlimited Access to Nicotine”Psychopharmacology,133:300-305 (1997).
Eliot L. Gardner, “6 Brain Reward Mechanisms”,Substance Abuse: A Comprehensive Textbook,p. 51-85 (1997).
Marshall et al., “Presynaptic Nicotinic Modulation of Dopamine Release in the Three Ascending Pathways Studied by In Vivo Microdialysis: Comparison of Naive and Chronic Nicotine-Treated Rats”Journal of Neurochemistry,68:1511-1519 (1997).
M.-F. Chesselet, “Presynaptic Regulation of Neurotransmitter Release in the Brain”,Neuroscience12:347-375 (1984).
Lacey et al., “On the Potassium Conductance Increase Activated by GABAband Dopamine D2Receptors in Rat Substantia Nigra Neurones”Journal of Physiology401:437-453 (1988).
Grant et al., “Vigabatrin: A Review of its Pharmacodynamic an Pharmacokinetic Properties, and Therapeutic Potential in Epilepsy and Disorders of Motor Control”Drugs41 6:889-926 (1991).
Jung et al., “Vinyl GABA (4-amino-hex-5-enoic acid). A New Selective Irreversible Inhibitor of GABA-T: Effects on Brain GABA Metabolism in Mice”Neurochem.29:797-802 (1977).
Roberts et al., “Baclofen Suppression of Cocaine Self-Administration: Demonstration Using a Discrete Trials Procedure”Psychopharmacology131:271-277 (1997).
Bolser et al., “The Pharmacology of SCH 50911: A Novel, Orally-Active GABA-B Receptor Antagonist”The Journal of Pharmacology and Experimental Therapeutics274:1393-1398 (1995).
Roberts et al., “Baclofen Attenuates the Reinforcing Effects of Cocaine in Rats”Neuropsychopharmacology15:417-423 (1996).
Derek van der Kooy, “Place Conditioning: A Simple and Effective Method for Assessing the Motivational Properties of Drugs”M.A. Bozarth, Ed., Springer-Verlag, New York,pp. 229-241 (1987).
Hurt et al., “A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation”The New England Journal of Medicine337:1195-1202 (1997).
Volkow et al., “Imaging Endogenous Dopamine Competition With [11C] Raclopride in the Human Brain”Synapse16:255-262 (1994).
Logan et al., “Graphical Analysis of Reversible Radioligand Binding from Time-Activity Measurements Applied to [N-11C-methyl]-(-)-Cocaine PET Studies in Human Subjects”Journal of Cerebral Blood Flow and Metabolism10:740-747 (1990).
Dewey et al., “A Novel Strategy for the Treatment of Cocaine Addiction”Synapse30:119-129 (1998).
Dewey et al., “Striatal Binding of the PET Ligand11C-Raclopride is Alter
Ashby, Jr. Charles R.
Brodie Jonathan D.
Dewey Stephen L.
Bogsian Margaret C.
Brookhaven Science Associates LLC
Criares Theodore J.
LandOfFree
Treatment of addiction and addiction-related behavior does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of addiction and addiction-related behavior, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of addiction and addiction-related behavior will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3399431